These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 34732251)

  • 1. Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma.
    Tucker MD; Brown LC; Chen YW; Kao C; Hirshman N; Kinsey EN; Ancell KK; Beckermann KE; Davis NB; McAlister R; Schaffer K; Armstrong AJ; Harrison MR; George DJ; Rathmell WK; Rini BI; Zhang T
    Biomark Res; 2021 Nov; 9(1):80. PubMed ID: 34732251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Impact of Baseline Neutrophil-to-Eosinophil Ratio in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Therapy in Second or Later Lines.
    Gil L; Alves FR; Silva D; Fernandes I; Fontes-Sousa M; Alves M; Papoila A; Da Luz R
    Cureus; 2022 Feb; 14(2):e22224. PubMed ID: 35340486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab/nivolumab.
    Beulque Y; Kinget L; Roussel E; Mobaraki S; Laenen A; Debruyne PR; Van Herck Y; Baldewijns M; Wozniak A; Garg AD; Zucman-Rossi J; Couchy G; Albersen M; De Wever L; Haaker L; Beuselinck B
    Acta Oncol; 2024 Aug; 63():658-668. PubMed ID: 39129249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
    Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma.
    Chen YW; Tucker MD; Brown LC; Yasin HA; Ancell KK; Armstrong AJ; Beckermann KE; Davis NB; Harrison MR; Kaiser EG; McAlister RK; Schaffer KR; Wallace DE; George DJ; Rathmell WK; Rini BI; Zhang T
    Cancers (Basel); 2022 Aug; 14(15):. PubMed ID: 35954493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program.
    Rebuzzi SE; Signori A; Buti S; Banna GL; Murianni V; Damassi A; Maruzzo M; Giannarelli D; Tortora G; Galli L; Rizzo M; De Giorgi U; Antonuzzo L; Bracarda S; Cartenì G; Atzori F; Tamberi S; Procopio G; Fratino L; Lo Re G; Santoni M; Baldessari C; Astone A; Calabrò F; Brunelli M; Porta C; Rescigno P; Basso U; Fornarini G
    ESMO Open; 2022 Dec; 7(6):100634. PubMed ID: 36493602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Zhuang TZ; Ravindranathan D; Liu Y; Martini DJ; Brown JT; Nazha B; Russler G; Yantorni LB; Caulfield S; Carthon BC; Kucuk O; Master VA; Bilen MA
    Oncologist; 2023 Mar; 28(3):239-245. PubMed ID: 36427017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab.
    Brown LC; Desai K; Wei W; Kinsey EN; Kao C; George DJ; Rini BI; Ornstein MC; Zhang T
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma.
    Ishihara H; Kondo T; Nakamura K; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Takagi T
    Jpn J Clin Oncol; 2021 Dec; 51(12):1751-1756. PubMed ID: 34492101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
    Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
    Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study.
    Iinuma K; Kameyama K; Kawada K; Fujimoto S; Takagi K; Nagai S; Ito H; Ishida T; Kawase M; Kawase K; Nakai C; Kato D; Takai M; Nakane K; Koie T
    Curr Oncol; 2021 Apr; 28(2):1402-1411. PubMed ID: 33916792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients.
    Thana M; Basappa NS; Ghosh S; Kollmannsberger CK; Heng DYC; Hansen AR; Graham J; Soulières D; Reaume MN; Lalani AA; Castonguay V; Bjarnason GA; Patenaude F; Breau RH; Pouliot F; Kapoor A; Wood LA
    Clin Genitourin Cancer; 2022 Jun; 20(3):210-218. PubMed ID: 35115252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study.
    Ishihara H; Nemoto Y; Nakamura K; Ikeda T; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Takagi T; Ishida H; Kondo T; Tanabe K
    Target Oncol; 2021 Jul; 16(4):493-502. PubMed ID: 34173936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus Nivolumab.
    McManus HD; Zhang D; Schwartz FR; Wu Y; Infield J; Ho E; Armstrong AJ; George DJ; Kruse D; Gupta RT; Harrison MR
    Clin Genitourin Cancer; 2023 Dec; 21(6):e429-e437.e2. PubMed ID: 37271698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214.
    Escudier B; Motzer RJ; Tannir NM; Porta C; Tomita Y; Maurer MA; McHenry MB; Rini BI
    Eur Urol; 2020 Apr; 77(4):449-453. PubMed ID: 31732098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab.
    Simonaggio A; Elaidi R; Fournier L; Fabre E; Ferrari V; Borchiellini D; Thouvenin J; Barthelemy P; Thibault C; Tartour E; Oudard S; Vano YA
    Cancer Immunol Immunother; 2020 Dec; 69(12):2513-2522. PubMed ID: 32561968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil-to-eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti-PD-1 therapy.
    Pozorski V; Park Y; Mohamoud Y; Tesfamichael D; Emamekhoo H; Birbrair A; Albertini MR; Ma VT
    Pigment Cell Melanoma Res; 2023 Nov; 36(6):501-511. PubMed ID: 37903733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study.
    Kato T; Fujita K; Minami T; Nagahara A; Hyashi Y; Nakata W; Matsuzaki K; Nakano K; Hatano K; Kawashima A; Imamura R; Takada S; Nishimura K; Tsujihata M; Takao T; Nakai Y; Nakayama M; Nishimura K; Uemura M; Uemura H; Nonomura N
    Int J Clin Oncol; 2022 Oct; 27(10):1596-1604. PubMed ID: 35831538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.